Cetaben is a PPARα-independent peroxisome proliferator. Cetaben is a non-fibrate hypolipidemic drug and potently reduces the concentration of cholesterol and triglycerides.

Product information

CAS Number: 55986-43-1

Molecular Weight: 361.56

Formula: C23H39NO2

Chemical Name: 4-(hexadecylamino)benzoic acid

Smiles: CCCCCCCCCCCCCCCCNC1C=CC(=CC=1)C(O)=O

InChiKey: QXWKHSSBFQDQPR-UHFFFAOYSA-N

InChi: InChI=1S/C23H39NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-20-24-22-18-16-21(17-19-22)23(25)26/h16-19,24H,2-15,20H2,1H3,(H,25,26)

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: DMSO : 25 mg/mL (69.14 mM; Need ultrasonic).

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

Cetaben (10 µM; 24 hours) induces severe micromorphological and ultrastructural changes in HepG2 and MH1C1 cells. After treatment with 100 µM cetaben, cells contained several Golgi regions, most of them disintegrated into vesicles. Cetaben-treated (10 µM; 24 hours) cells were characterized by a striking heterogeneity of the peroxisomal population with the occurrence of dumbbell-shaped and cup-shaped peroxisomal profiles in MH1C1cells.

In Vivo:

Cetaben reveales a significant rise in the activities of peroxisomal enzymes in both the liver and kidney at doses of 50-100 mg/kg body over 10 days, but the maximal effect is observed at 250 mg/kg.

Products are for research use only. Not for human use.